drugset / Trial / NCT06594432
Molecular Subtype-Guided R-CHOP-MTX±Zanubrutinib Treatment in Newly Diagnosed DLBCL Patients with Central Nervous System Involvement
Phase 2
Not yet recruiting
40 enrolled
The First Affiliated Hospital with Nanjing Medical University
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Evaluate the Efficacy and Safety of R-CHOP-MTX±Zanubrutinib in Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients with Central Nervous System Involvement, and Explore the Efficacy Indicators of CSF-ctDNA.
Timeline
- Start
- 2024-10
- Primary completion
- 2026-12
- Completion
- 2027-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zanubrutinib | Small molecule | — | — |
| Background | Lenalidomide | Other / unclassified | — | — |
| Background | MTX | Unknown | — | — |
| Background | Pomalidomide | Other / unclassified | — | — |
| Background | Rituximab | Monoclonal antibody | — | — |
| Background | Temozolomide | Small molecule | — | — |